Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 12, 2018

Primary Completion Date

September 7, 2022

Study Completion Date

September 7, 2022

Conditions
Heart Failure
Interventions
DRUG

Lysine Chloride

Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.

OTHER

Placebo

Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.

Trial Locations (1)

06510

Yale University, New Haven

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Yale University

OTHER

NCT03446651 - Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure | Biotech Hunter | Biotech Hunter